echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > BMJ: Have immunosuppressant side effects? Scientists have found that Treg cells suppress immunity!

    BMJ: Have immunosuppressant side effects? Scientists have found that Treg cells suppress immunity!

    • Last Update: 2020-11-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The immune system protects the body from external factors.
    , when the body's immunity is too strong, it can also cause damage to the body, leading to the occurrence of autoimmune diseases.
    note that the immune system's defense of external organs after an organ transplant causes problems, making them need to be treated with immunosuppressants.
    refore, chronic rejection and chronic immunosuppression of long-term complications (e.g. infection, malignant tumors, cardiovascular disease, etc.) are the key points to be solved, people are constantly looking for new treatment strategies.
    BMJ published a study by the Petra Reinke team at The University of Berlin in Berlin called "Regulatory T cells forminimising immune suppression in transplantation: phase I/IIa clinicaltrial", which found that naturally regulated T-cells (nTreg) reduced immunosuppressant use in patients after kidney transplantation.
    previous studies have found that nTreg has a therapeutic effect in patients after organ transplantation.
    In this study, the researchers applied autolognation CD4, CD25, and FoxP3, nTreg to 11 patients who received a kidney transplant to observe its safety and ability, and to assess whether nTreg could reduce the amount of immunosuppressants in patients within 48 weeks of transplantation.
    the safety of nTreg therapy after the use of immunosuppressants in patients after self-infusion minimized kidney transplantation.
    dose-dependent toxicity was not found in all 3 nTreg treatment groups.
    survival rate was 100% after allogeneic transplantation in the nTreg treatment group and the control group, and no serious adverse reaction events were reported.
    the patients were biomarker analyzed by researchers in the nTreg treatment group and the control group, nTreg therapy had no significant effect on other immunocell subgroups compared to the control group.
    analysis of biomarkers in patients in the nTreg treatment group and control group, this study shows that this nTreg is safer, has good tolerance, and can reduce the use of immunosuppressants.
    Of course, in order to further improve the efficacy and stability of the therapy, more research is needed to explore the sustainable and functional transplantation of Tregs, specificity, and resistance to immunosuppressive drugs, and to study their optimal dose.
    in the near future, patients with organ transplants can reduce the use of immunosuppressants by auto-transplanting immune cells to avoid their side effects.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.